



Supplemental Figure 1: Individual value plots for laboratory findings


A. Proteinuria at presentation



B. Creatinine at presentation




C. Complement levels at presentation




Supplemental Figure 2: Pedigrees for familial cases

A: NCL25 (II:2)



■ aHUS
● δ *DGKE* c.463A>G p.(Arg155Gly)
● \dagger *DGKE* c.1427T>C p.(Leu476Pro)
○ wt: wild type

B: NCL26 (II:8)



■ aHUS

yrs = age (years) when died

¶ *DGKE* c.826delG p.(Val276Phefs*8)

wt: wild type

NCL26 pedigree: additional clinical information

II:2

- Died aged 5 ½ months
- Death certificate recorded “Recurrent haemolytic uraemic syndrome and malignant hypertension”
- Blood tests before his death showed anaemia, kidney failure with a few fragments and burr cells, and thrombocytopaenia
- Kidney biopsy showed very large quantities of fibrillary material between the basement membranes and endothelial cells, extending into mesangial areas and also some ‘formed, spherical, electron dense particles’ in places; appearances were felt to be consistent with HUS


II:4

- Presented aged 3 ½ months with anaemia
- Presented aged 10 months with oedema and proteinuria; diagnosed with ‘mild HUS’
- Episode of oedema after a measles vaccination
- Presented aged 18 months with febrile episode, oedema and vomiting
 - Haemolysis and AKI
 - Consent was not given for dialysis
 - Deteriorated with convulsions, anuria, and AKI
 - Then had peritoneal dialysis but remained ill with poorly controlled hypertension and heart failure
 - Subsequently had a cardiac arrest and died

II:6

- Presented aged 7 months with proteinuria and haemolysis
- HUS ‘gradually came under control’
- Relapse aged 3 years: presented with vomiting and diarrhoea
 - HUS was diagnosed 10 days later, complicated by pulmonary oedema, heart failure and *E. coli* urinary tract infection
- Relapse aged 3 years 6 months
 - Consent was not given for dialysis
 - Died 1 month later


C: NCL27 (III:1) and NCL29 (III:2)



aHUS/MPGN

Δ *DGKE* c.1597A>C p.(Thr533Pro)
wt: wild type

D: NCL34 (II:4)



■ aHUS


yrs = current age (2019)

◊ *DGKE* c.1647_1650delAACAA p.(T550Mfs*13)

Supplemental Figure 3: Sanger sequencing traces


A. NCL25. a. *DGKE* exon 2. b. *DGKE* exon 11.

a.




Reference base sequence
NCL25 base sequence

b.




NCL25 amino acid sequence
Reference amino acid sequence



DGKE c.463A>G p.(R155G)

Reference sequence chromatogram

NCL25 chromatogram



DGKE c.1427T>C p.(L476P)


B. NCL27. DGKE exon 12

CCTTGGGCCCAAGGGCCCTGCACTGTCACCATAACTCACAAAGACACATGCAATGATGTT
CCTTGGGCCCAAGGGCCCTGCACTGTCCCCATAACTCACAAAGACACATGCAATGATGTT

Reference base sequence
NCL27 base sequence

1750 1760 1770 1780 1790 1800
CCTTGGGCCCAAGGGCCCTGCACTGTCACCATAACTCACAAAGACACATGCAATGATGTT
P W A Q G P C T V P I T H K T H A M M L
P W A Q G P C T V I T H K T H A M M L

NCL27 amino acid sequence
Reference amino acid sequence



Reference sequence chromatogram

NCL27 chromatogram

DGKE c.1597A>C p.(T533P)

C. NCL29. DGKE exon 12

CCTTGGGCCCAAGGGCCCTGCACTGTCACCATAACTCACAAAGACACATGCAATGATGTT
CCTTGGGCCCAAGGGCCCTGCACTGTCACCATAACTCACAAAGACACATGCAATGATGTT


Reference base sequence

NCL29 base sequence

1750 1760 1770 1780 1790 1800
CCTTGGGCCCAAGGGCCCTGCACTGTCACCATAACTCACAAAGACACATGCAATGATGTT
•
P W A Q G P C T V P I T H K T H A M M L
P W A Q G P C T V I T H K T H A M M L

NCL29 amino acid sequence

Reference amino acid sequence

C T G C A C T G T C A C C A T A A A C T C A C C A
C T G C A C T G T C A C C A T A A A C T C A C C A


Reference sequence chromatogram

SS15_67174-02_D196379_(12)x012_DGKE_F_M03_20 Fragment base #1,777. Base 148 of 434
C T G C A C T G T C C C A T A A C T C A C C A
C T G C A C T G T C C C A T A A C T C A C C A




NCL29 chromatogram



DGKE c.1597A>C p.(T533P)


D. NCL30. a. DGKE exon 2. b. DGKE exon 3.

a.




DGKE c.393C>G p (N131K)

b.



Reference sequence chromatogram

NCL30 chromatogram




DGKE c.465-2A>G

E. NCL31. DGKE exon 2



Reference base sequence
NCL31 base sequence


NCL31 amino acid sequence
Reference amino acid sequence



NCL31 chromatogram

DGKE c.325A>G p.(K109E)

F. NCL33. DGKE exon 6




Reference base sequence

NCL33 base sequence

NCL33 amino acid sequence

Reference amino acid sequence




Reference sequence chromatogram

NCL33 chromatogram

DGKE c.966G>A p.(Trp322)*

G. NCL34. DGKE exon 12




Reference base sequence

NCL34 base sequence

NCL34 amino acid sequence

Reference amino acid sequence




Reference sequence chromatogram

NCL34 chromatogram

DGKE c.1647_1650delAACAA p.(T550Mfs*13)



H. NCL36. a. *DGKE* exon 6. b. *DGKE* exon 11.

a.




DGKE c.966G>A p.(Trp322*)

b.




DGKE c.1524+2T>C

I. NCL37. DGKE exon



Reference base sequence
NCL37 base sequence




Reference sequence chromatogram

NCL37 chromatogram


DGKE c.323G>A p.(C108Y)

J. NCL38. DGKE exon 6



Reference base sequence
NCL38 base sequence

NCL38 amino acid sequence
Reference amino acid sequence





Reference sequence chromatogram

NCL38 chromatogram

DGKE c.966G>A p.(Trp322*)


K. NCL39. a. DGKE exon 3. b. DGKE exon 6.

a.




DGKE c.465-2A>G

b.




Reference sequence chromatogram

NCL39 chromatogram





DGKE c.966G>A p.(Trp322*)

L. NCL40. *DGKE* exon 6



NCL40 amino acid sequence
Reference amino acid sequence



NCL40 chromatogram

DGKE c.966G>A p.(Trp322*)

Supplemental Figure 4: DGKE amino acid conservation alignments for newly described missense mutations

A. NCL25. i. R155G. ii. L476P

i.

Species	Amino acid sequence										
	K 150	L 151	C 152	D 153	Y 154	G 155	C 156	I 157	W 158	C 159	Q 160
Human	K	L	C	D	Y	R	C	I	W	C	Q
Chimp	K	L	C	D	Y	R	C	I	W	C	Q
Gorilla	K	L	C	D	Y	-	-	-	-	-	-
Orangutan	K	L	C	D	Y	R	C	I	W	C	Q
Rhesus Monkey	K	L	C	D	Y	R	C	I	W	C	Q
Mouse	K	L	C	D	Y	R	C	I	W	C	Q
Rat	K	L	C	D	Y	R	C	V	W	C	Q
Rabbit	K	L	C	D	Y	R	C	I	W	C	Q
Dolphin	K	L	C	D	Y	R	C	I	W	C	Q
Dog	K	L	C	D	Y	R	C	I	W	C	Q
Opossum	K	L	C	D	Y	R	C	I	W	C	Q
Platypus	K	L	C	D	Y	R	C	I	W	C	Q
Chicken	K	L	C	D	Y	R	C	V	W	C	Q
Zebrafish	K	L	C	D	Y	R	C	V	W	C	Q

ii.

Species	Amino acid sequence										
	R 471	H 472	D 473	D 474	G 475	P 476	L 477	E 478	V 479	V 480	G 481
Human	R	H	D	D	G	L	L	E	V	V	G
Chimp	R	H	D	D	G	L	L	E	V	V	G
Gorilla	R	H	D	D	G	L	L	E	V	V	G
Orangutan	R	H	D	D	G	L	L	E	V	V	G
Rhesus Monkey	R	H	D	D	G	L	L	E	V	V	G
Mouse	R	H	D	D	G	L	L	E	I	V	G
Rat	R	H	D	D	G	L	L	E	V	V	G
Rabbit	R	H	D	D	G	L	L	E	V	V	G
Dolphin	R	H	D	D	G	L	L	E	V	V	G
Dog	R	H	D	D	G	L	L	E	V	V	G
Opossum	S	H	D	D	G	L	L	E	V	V	G
Platypus	R	H	D	D	G	L	L	E	V	V	G
Chicken	R	H	D	D	G	L	L	E	V	V	G
Zebrafish	R	V	D	D	G	L	L	E	V	V	G

B. NCL27 and NCL29. T533P

Species	Amino acid sequence											
	G 528	P 529	C 530	T 531	V 532	P 533	I 534	T 535	H 536	K 537	T 538	
Human	G	P	C	T	V	T	I	T	H	K	T	
Chimp	G	P	C	T	V	T	I	T	H	K	T	
Gorilla	G	P	C	T	V	T	I	T	H	K	T	
Orangutan	G	P	C	T	V	T	I	T	H	K	T	
Rhesus Monkey	G	P	C	T	V	T	I	T	H	K	T	
Mouse	G	P	C	T	V	T	I	T	H	K	T	
Rat	G	P	C	T	V	T	I	T	H	K	T	
Rabbit	G	P	C	T	V	T	I	T	H	K	T	
Dolphin	G	P	C	T	V	T	I	T	H	K	T	
Dog	G	P	C	T	V	T	I	T	H	K	T	
Opossum	G	P	C	I	V	T	I	T	H	K	T	
Platypus	G	P	C	T	V	T	I	T	H	K	T	
Chicken	G	P	C	T	V	T	I	T	H	K	T	
Zebrafish	G	P	C	T	I	T	I	T	H	K	T	

C. NCL28. M1L

Species	Amino acid sequence					
	L 1	E 2	A 3	E 4	R 5	R 6
NCL36	M	E	A	E	R	R
Human	M	E	A	E	R	R
Chimp	M	E	A	E	R	R
Gorilla	M	E	A	E	R	R
Orangutan	M	E	A	E	R	R
Rhesus Monkey	M	E	A	E	R	R
Mouse	M	E	G	D	Q	R
Rat	M	E	G	D	Q	R
Rabbit	M	E	G	E	R	R
Dolphin	M	E	G	E	K	R
Dog	M	E	A	E	R	R
Opossum	M	E	G	R	K	Q
Platypus	M	E	R	G	E	P
Chicken	M	L	P	E	A	A
Zebrafish	M	E	E	N	N	E

D. NCL30. N131K

Species	Amino acid sequence											
	NCL30	H 126	W 127	I 128	R 129	G 130	K 131	V 132	P 133	L 134	C 135	S 136
Human	H	W	I	R	G	N	V	P	L	C	S	
Chimp	H	W	I	R	G	N	V	P	L	C	S	
Gorilla	H	W	I	R	G	N	V	P	L	C	S	
Orangutan	H	W	I	R	G	N	V	P	L	C	S	
Rhesus Monkey	H	W	I	R	G	N	V	P	L	C	S	
Mouse	H	W	I	R	G	N	V	P	L	C	S	
Rat	H	W	I	R	G	N	V	P	L	C	T	
Rabbit	H	W	I	R	G	N	V	P	L	C	S	
Dolphin	H	W	I	R	G	N	V	P	L	C	S	
Dog	H	W	I	R	G	N	V	P	L	C	S	
Opossum	H	W	I	R	G	N	V	P	L	C	S	
Platypus	R	W	I	R	G	N	V	P	L	C	S	
Chicken	H	W	I	R	G	N	V	P	L	C	S	
Zebrafish	Q	W	V	K	G	N	V	P	L	A	S	

E. NCL32. Q79P

Species	Amino acid sequence											
	C	C	V	C	A	P	H	I	81	L	82	Q
NCL32	C 74	C 75	V 76	C 77	A 78	P 79	H 80	I	81	L 82	Q 83	G 84
Human	C	C	V	C	A	Q	H	I		L	Q	G
Chimp	C	C	V	C	A	Q	H	I		L	Q	G
Gorilla	C	C	V	C	A	Q	H	I		L	Q	G
Orangutan	C	C	V	C	A	Q	H	I		L	Q	G
Rhesus Monkey	C	C	V	C	A	Q	H	I		L	Q	G
Mouse	C	C	V	C	A	Q	H	I		L	Q	G
Rat	C	C	V	C	A	Q	H	I		L	Q	G
Rabbit	C	C	V	C	A	Q	H	I		L	R	G
Dolphin	C	C	V	C	A	Q	H	I		L	Q	G
Dog	C	C	V	C	A	Q	H	I		L	L	G
Opossum	C	C	V	C	T	Q	H	I		L	Q	G
Platypus	C	C	L	C	A	Q	H	I		L	R	G
Chicken	C	C	V	C	A	Q	H	I		L	R	G
Zebrafish	C	C	V	C	C	Q	P	I		L	Q	G

F. NCL37. C108Y

Species	Amino acid sequence										
	D	K	R	F	Q	Y	K	E	I	M	L
NCL37	D 103	K 104	R 105	F 106	Q 107	Y 108	K 109	E 110	I 111	M 112	L 113
Human	D	K	R	F	Q	C	K	E	I	M	L
Chimp	D	K	R	F	Q	C	K	E	I	M	L
Gorilla	D	K	R	F	Q	C	K	E	I	M	L
Orangutan	D	K	R	F	Q	C	K	E	I	M	L
Rhesus Monkey	D	R	R	F	Q	C	K	E	I	M	L
Mouse	D	K	R	F	P	C	K	E	I	M	L
Rat	D	K	R	F	P	C	K	E	I	M	L
Rabbit	D	R	R	F	A	C	K	E	I	V	L
Dolphin	D	K	R	F	H	C	K	E	I	M	L
Dog	D	K	R	F	P	C	K	E	I	M	L
Opossum	D	R	Q	F	Q	C	K	E	I	M	L
Platypus	D	R	R	F	P	C	K	E	I	M	L
Chicken	D	Q	H	F	L	C	K	E	I	V	M
Zebrafish	D	R	I	L	S	C	K	E	I	M	T


Supplemental Table 1: *In silico* analysis of newly described missense DGKE mutations

Patient	Inheritance	DGKE variant	ESP frequencies	Align GVGD	SIFT	MutationTaster
NCL25	Compound heterozygous	c.463A>G p.(Arg155Gly)¶	N/A	Class C65 (GV: 0.00 - GD: 125.13)	Deleterious (score: 0)	Disease causing (p-value: 1)
		c.1427T>C p.(Leu476Pro)¶	N/A	Class C45 (GV: 14.30 - GD: 86.59)	Deleterious (score: 0.01)	Disease causing (p-value: 1)
NCL26	Homozygous	c.826delG p.(Val276Phefs*8)¶	N/A	NA: frameshift		
NCL27	Homozygous	c.1597A>C p.(Thr533Pro)¶	N/A	Class C0 (GV: 121.10 - GD: 28.88)	Tolerated (score: 0.23)	Disease causing (p-value: 1)
NCL28	Homozygous	c.1A>T p.(Met1Leu)¶	N/A	NA: start loss		
NCL29	Homozygous	c.1597A>C p.(Thr533Pro) ¶	N/A	Class C0 (GV: 121.10 - GD: 28.88)	Tolerated (score: 0.23)	Disease causing (p-value: 1)
NCL30	Compound heterozygous	c.393C>G p.(Asn131Lys)¶	N/A	Class C65 (GV: 0.00 - GD: 93.88)	Deleterious (score: 0)	Disease causing (p-value: 1)
		c.465-2A>G ¶	N/A	NA: splice site		
NCL32	Homozygous	c.236A>C p.(Gln79Pro)¶	N/A	Class C0 (GV: 261.33 - GD: 0.00)	Tolerated (score: 0.14)	Disease causing (p-value: 1)
NCL34	Homozygous	c.1647_1650delAACAA p.(Thr550Metfs*13)¶	N/A	NA: frameshift		
NCL37	Homozygous	c.323G>A p.(Cys108Tyr)¶	N/A	Class C65 (GV: 0.00 - GD: 193.72)	Deleterious (score: 0)	Disease causing (p-value: 1)


Abbreviations: DGKE, diacyl glycerol kinase E; ESP, Exome Sequencing Project; GVGD, Grantham Variation Grantham Difference; NA, not applicable; N/A, not available; SIFT, Sorting Tolerant From Intolerant.

Supplemental Figure 5: Kaplan Meier Survival Curves


A. Renal survival comparing individuals who received eculizumab with those who did not




B. Renal and patient survival, including individuals for whom no genetic analysis was possible



C. Renal and patient survival, including individuals for whom no genetic analysis was possible, comparing individuals who received eculizumab with those who did not



D. Renal survival, incorporating data published by Azukaitis et al., for all published DGKA nephropathy cases



Supplemental Figure 6: Primer design for RNA studies

A. c.1524+2T>C

CTCCAGCTCGGGCCCCGCGGCCGGATCGCGTGCCTGGAGCCTTAAGCGTTCCCCGCC
CGGCTTCATCCCTGCTGGCGGCCAGCGTCGTTCTCCCTCGCGCAGGGCGCCAAGGCCTGCTGGCC
CGGAGCCGCGCCTCACCCCGCGCAG **GTATCGTCCTTGAGAAGATGGAAGCGGAGAGGCCGGCG**
CCGGGCTCGCCCTCCGAGGGCTGTTGCGGACGGCACCTGATCTTGTGGACGCTGTGCTCGGTCT
GCTGCCGTGTTCATCACCTCTGGTGTAGCCTCCAGCGTCGCGCCGGCAGCTGCACCGCAGGGACA
TCTTCCGCAAGAGCAAGCACGGGTGGCGCACACGGACCTGTTAGCCAGCCCACCTACTGCTGCGTG
TGC CGCAGCACATTCTGCAGGGCGCTCTGCACTGCTGCGGGCTCCGCGTGGACGAGGGCTGCCT
CAGGAAGGCCGACAAGCGCTTCAGTGCAAGGAGATTATGCTCAAG **AAATGACACCCAAGGTCTGGACG**
CCATGCCCAACCACGGATCCGGGCAACGTGCCCTGTGCAGTTACTGTATGGTTGCAAGCAGCAG
TGTGGCTGTCAACCCAAGCTTGCGATTACAG **GTGCATTGGTGCAGAAAACAGTACATGATGAGTG**
CATGAAAAATAGTTAAAGAATGTAAGACAAAAATGTTGGAGAATTCAAAAACCTAATCATTCCACCAA
GTTATTAAACATCCATTAAATCAGATGCGTAAAGACAAAAAACAGATTATGAAGTG **CTAGCCTCTAAG**
CTTGGAAAGCAGTGACCCCATTAATAATCCTGGCAACTCTCGTAGTGGAAACTAATATGGGAGAAGG
ACTGTTGGGAGAATTAGGATCTTGTGAATCCAGTCAGGTTGGATGTAACTAAACT**CCTCCTA**
TCAAAGCCCTACAACTCTGTACTCTCTCCCATAATTATTCACTCGAGTACTTGTGAGGGGAT
GGGACTGTAGGGTGGGTCTGGATGCAGTTGATGACATGAAGATTAAAG **GGACAAGAAAAGTACATTCC**
ACAAGTGCAGTTGCTCTGGGACAGGCAACGATCTATCCAATACATTGGGTTGGGTACAGGTT
ATGCTGGAGAAATTCCAGTTGCGCAGGTTGCGAAATGTAATGGAAGCAGATGGAATTAAACTAGAT
CG

exon 1 - 162 bp

exon 2 - 482 bp

exon 3 - 160 bp

exon 4 - 120 bp

exon 5 - 144 bp

exon 6 - 158 bp

predict exon 3 del - 318 bp

WT - 478 bp

DGKE_RNA_Ex2-5f gtagcgcgacggccagtGAATGACACCAAGGTCTGG

DGKE_RNA_Ex2-5r cagggcgcagcgatgactGTAGGGCTTGATAGGAGG

B. c.465-2A>G

GC GGTTTACTTATTCTAT**GGAACCAAAGATTGTTAGTGC**AAGAATGTAAAGATTGAATAAAAAAGTTGAGCTA
GA ACTGGATGGTGAGCGAGTAGCACTGCCAGCTTGAAGGTATTATAGTTCTGAACATCGGATACTGGGGCGGT
GGCTGCAGACTATGGGAAGGGATGGGGACGAGACTTACCCCTCTAGCCAG**GCATGACGATGGCTGCTGGAAGTC**
GTTGGAGTATATGGGTCTTCCACTGTGCTCAGATTCAAGTAAAACTGGCTAATCCTTTGAAATAGGACAGGCA
CATACAGTGAGGCTGATTTGAAGTGCTCCATGATGCCAATGCAGGTGGATGGGAGCCTGGGCCAAGGGCCC
TGCACGTGTCACCATAA**CTCACAAGACACATGCAATGA**TGTTATATTCTCTGGAGAACAAACAGATGATGACATC
TCTAGTACTTCGGATCAAGAAGATATAAAGCGACTGAATAG**ATGGATGAGGGAGT**AAAACCTTGCATAGAAC
CTCACGCAAGTAGATA**CATGTTCATC**AAAAGTATTAA**TAGAA**ATTCTCTATCAGCTATTCACTTAC
TAGTAGTATAATGGGTACATTTGTAATAGCATCCCCAAACCAGCCAGCCTCAGTTATTACAAATGTT
GTTCTTTTTTCAGCAAAACTTCAAATGAATAGTATTAACTTACAAAAGTCACAAAACATTACATGAGAGTGA
AAATTGTTATGACTGTTTGAGAGTGGGACTCACTCTGAAGTATGTGCTGTCATGTCTTATTGGAAACCAT
GCATATGATGGACACACAATGGATGGACACATTATATCTCCAACAAGGTGTGGGTGAAAGATCAAATTAACCTG
CTTTTGAAAGGAAATGATTACTGTCAAACCAGCATGGTTAATTGTGAGCATTCTCC

predicted to lose exon 11 = 112bp or get an extra 4 bases on end of exon 11

Expected product

WT = 428 bp

first 43 bases exon 10 to exon 12 = 215 bp

inclusion of intron 11 = 788 bp

DGKE_RNA_Ex9f gtagcgcgacggccagt**GGAACCAAAGATTGTTAGTGC**

DGKE_Ex10_12f gtagcgcgacggccagt**TGGATGGTGAGCGAGTAGC**

DGKE_Ex10_12r cagggcgcagcgatgac**TCATTGCATGTGCTTGTGAG**